Thank you for attending THSNA 2026. The virtual meeting is now closed.
Use this page to browse all contributing authors.
Presentations for Cédric Hermans
Evaluating pen-injector handling and PROs in patients switching from emicizumab to Mim8 in FRONTIER5 |
From Efficacy to Experience: 52-Week Patient-Reported Outcomes with Mim8 in Adolescents and Adults with Hemophilia A with or without Inhibitors (FRONTIER2) |